Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) to a strong-buy rating in a research note published on Thursday morning,Zacks.com reports.

Separately, Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $9.00 target price for the company.

Eupraxia Pharmaceuticals Trading Up 8.0 %

NASDAQ EPRX opened at $3.13 on Thursday. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $5.58. The stock has a market cap of $85.41 million and a PE ratio of -4.35. The stock’s 50 day moving average is $2.67 and its 200 day moving average is $2.68.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC acquired a new position in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 13,000 shares of the company’s stock, valued at approximately $34,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.